Skip to main content

Table 3 Bayesian Analysis of Change from Baseline SGRQ Score up to Month 6

From: CXCR2 antagonist for patients with chronic obstructive pulmonary disease with chronic mucus hypersecretion: a phase 2b trial

 PlaceboDNX 5 mgDNX 10 mgDNX 25 mgDNX 35 mgDNX 50 mg
N10110210010310099
Baseline SGRQ Total Score46.21 (17.426)47.16 (16.057)45.97 (14.991)48.47 (17.514)47.18 (15.871)46.19 (16.669)
n859686908685
Mean Change from Baseline (90% CI)−4.11 (−6.25,-2.00)−3.44 (−5.51,-1.38)−4.19 (−6.28,-2.12)−4.94 (−7.03,-2.91)−4.12 (−6.22,-1.99)−3.41 (−5.55,-1.26)
Mean Difference from Placebo (90% CI) 0.68 (−2.26,3.67)−0.08 (− 3.05,2.84)−0.83 (− 3.81,2.09)−0.01 (− 3.06,2.97)0.70 (−2.33,3.76)
  1. N Number enrolled, n Number of subjects with analysable data at the current time point; CI Credible interval